Deferiere Raphael 4

4 · Centessa Pharmaceuticals plc · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Centessa (CNTA) Chief Accounting Officer Raphael Deferiere Receives 53,000 Equity Awards

What Happened

Raphael Deferiere, Chief Accounting Officer of Centessa Pharmaceuticals plc (CNTA), was granted a total of 53,000 equity awards on February 2, 2026. The filing shows 11,000 shares reported as a grant (RSUs) and 42,000 reported as derivative awards; the reported acquisition price for both lines is $0. These are compensation awards, not open-market purchases or sales.

Key Details

Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (filed the next day).
Grants reported: 11,000 RSUs (grant) and 42,000 derivative awards; acquisition price $0 for each line.
Post-transaction holdings: not specified in the provided filing details.
Footnotes of note:
- F1: Ordinary Shares may be represented by American Depositary Shares (each ADS currently equals one Ordinary Share).
- F2: The 11,000 share grant represents Restricted Share Units (RSUs); each RSU is a contingent right to one Ordinary Share and will vest/settle in four equal annual installments beginning Feb 2, 2027.
- F3: The 42,000 derivative awards vest monthly at 1/48th per month, with the first monthly vesting on March 2, 2026.
Transaction code: A (award/grant). No sale or purchase reported; no immediate cash proceeds.

Context

RSUs and derivative awards are compensation that convert to actual shares only as they vest; they do not represent an immediate purchase or sale and therefore are not a direct bullish/bearish market signal by themselves.
The derivative line appears to follow a 4-year monthly vesting schedule (standard service-based vesting); the RSUs follow a 4-year annual cliff-style schedule starting in 2027.
Filing was timely (reported the day after the transaction).

Form 4

Period: 2026-02-02

Chief Accounting Officer

Transactions

Award
Ordinary Shares
[F1][F2]
2026-02-02+11,000→ 11,000 total
Award
Share Option (right to buy)
[F3][F1]
2026-02-02+42,000→ 42,000 total
Exercise: $25.19Exp: 2036-02-02→ Ordinary Shares (42,000 underlying)

Footnotes (3)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
[F3]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.

Signature

/s/ Raphael Deferiere|2026-02-03

1 file